[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100617626":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":11,"locations":17,"responsibleParty":41,"collaborators":10,"id":45,"slug":10,"hasResults":46,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":46,"sex":51,"minAge":52,"maxAge":10,"enrollmentInfo":53,"targetDuration":56,"studyType":57,"phases":10,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":64,"whyStopped":10,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":74},{"fullName":5,"class":6},"Sohag University","OTHER",[8],{"label":9,"type":10,"description":10,"interventionNames":10},"all patients diagnosed with advanced hepatocellular carcinoma eligible for ICIs",null,[12],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},"Ahmed Karam Helmy, MSc","CONTACT","2+01090784895","ahmed011028@med.sohag.edu.eg",[18,33],{"facility":19,"status":10,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":24,"geoPoint":29,"contacts":30},"Sohag university hospitals","Sohag","Sohag Governorate","82511","Egypt",{"type":25,"coordinates":26},"Point",[27,28],31.69478,26.55695,{"lat":28,"lon":27},[31],{"name":32,"role":14,"phone":15,"phoneExt":10,"email":16},"Ahmed Karam, MSc",{"facility":34,"status":10,"city":20,"state":21,"zip":22,"country":23,"cosmosGeoPoint":35,"geoPoint":37,"contacts":38},"sSohag oncology centre",{"type":25,"coordinates":36},[27,28],{"lat":28,"lon":27},[39,40],{"name":13,"role":14,"phone":15,"phoneExt":10,"email":16},{"name":13,"role":14,"phone":10,"phoneExt":10,"email":16},{"type":42,"investigatorFullName":43,"investigatorTitle":44,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"SPONSOR_INVESTIGATOR","Ahmed Karam Helmy","Use of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma : efficacy and outcomes","100617626",false,"NCT07321067","Use of Immune Checkpoint Inhibitors in Patients With Advanced Hepatocellular Carcinoma : Efficacy and Outcomes","ICIs","Inclusion Criteria:\n\n* Adults (≥18 years) with radiologically or histologically confirmed advanced HCC\n* Candidates for systemic immune checkpoint inhibitors (e.g., atezolizumab-bevacizumab, durvalumab-tremelimumab).\n* Patients with preserved liver function. ( up to G2 using ALBI score or up to B (7 ) using Child-Pugh socring system) .\n\nExclusion Criteria:\n\n* Child-Pugh C liver function.\n* Prior liver transplantation.\n* patients with concurrent malignancies other than HCC.\n* Active autoimmune disease requiring systemic immunosuppression.","ALL","18 Years",{"count":54,"type":55},75,"ESTIMATED","12 Months","OBSERVATIONAL","the Objectives of this study are:\n\n• Primary Objective: To prospectively evaluate overall survival (OS), ICI-specific survival (OS-ICI), and progression-free survival (PFS) in patients with advanced HCC treated with immune checkpoint inhibitors.\n\nthe main question it aims to answer is: What are the clinical outcomes (overall survival, progression-free survival, and OS-ICIs) of immune checkpoint inhibitor therapy in patients with advanced hepatocellular carcinoma? Participants already taking immune checkpoint inhibitors as part of their regular medical care.",[60],"Advanced Hepatocellular Carcinoma (HCC)",[62,63],"advanced hepatocellular carcinoma","immune checkpoint inhibitors","NOT_YET_RECRUITING","2025-12-21",{"date":67,"type":68},"2026-01-06","ACTUAL",{"date":70,"type":55},"2026-01-01",{"date":72,"type":55},"2027-11-01",{"name":43,"class":6},2]